Viral vectors engineered for gene therapy

Int Rev Cell Mol Biol. 2023;379:1-41. doi: 10.1016/bs.ircmb.2023.05.005. Epub 2023 Jul 1.ABSTRACTGene therapy has seen major progress in recent years. Viral vectors have made a significant contribution through efficient engineering for improved delivery and safety. A large variety of indications such as cancer, cardiovascular, metabolic, hematological, neurological, muscular, ophthalmological, infectious diseases, and immunodeficiency have been targeted. Viral vectors based on adenoviruses, adeno-associated viruses, herpes simplex viruses, retroviruses including lentiviruses, alphaviruses, flaviviruses, measles viruses, rhabdoviruses, Newcastle disease virus, poxviruses, picornaviruses, reoviruses, and polyomaviruses have been used. Proof-of-concept has been demonstrated for different indications in animal models. Therapeutic efficacy has also been achieved in clinical trials. Several viral vector-based drugs have been approved for the treatment of cancer, and hematological, metabolic, and neurological diseases. Moreover, viral vector-based vaccines have been approved against COVID-19 and Ebola virus disease.PMID:37541721 | DOI:10.1016/bs.ircmb.2023.05.005
Source: International Review of Cell and Molecular Biology - Category: Cytology Authors: Source Type: research